We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
GenMark Diagnostics Inc | NASDAQ:GNMK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.05 | 23.92 | 24.39 | 0 | 01:00:00 |
Delaware
|
|
27-2053069
|
(State or other jurisdiction
of incorporation)
|
|
(I.R.S. Employer
Identification No.)
|
5964 La Place Court
Carlsbad, California
|
(Address of principal executive offices, including zip code)
|
760-448-4300
|
(Registrant’s telephone number, including area code)
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
1.
|
For the proposal to elect two nominees for director to serve a three-year term expiring at GenMark’s 2020 Annual Meeting of Stockholders, the voting results were as follows:
|
Name of Directors Elected
|
|
For
|
|
Withhold
|
|
Broker Non-Votes
|
|
Daryl J. Faulkner
|
|
35,897,868
|
|
2,720,351
|
|
6,010,599
|
|
James Fox, Ph.D.
|
|
34,252,517
|
|
4,365,702
|
|
6,010,599
|
|
2.
|
For the proposal to ratify Ernst & Young LLP as GenMark’s independent registered public accounting firm for the fiscal year ending December 31, 2017, the voting results were as follows:
|
For
|
|
Against
|
|
Abstain
|
44,611,931
|
|
13,353
|
|
3,534
|
3.
|
For the proposal to approve, on an advisory basis, the compensation of GenMark’s named executive officers, the voting results were as follows:
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
25,186,020
|
|
13,424,536
|
|
7,663
|
|
6,010,599
|
4.
|
For the proposal to indicate, on an advisory basis, the preferred frequency with which GenMark should hold future stockholder advisory votes on the compensation of its named executive officers, the voting results were as follows:
|
1 Year
|
|
2 Years
|
|
3 Years
|
|
Abstain
|
37,327,656
|
|
1,725
|
|
1,287,600
|
|
1,238
|
May 31, 2017
|
GENMARK DIAGNOSTICS, INC.
|
|
|
|
|
|
/s/ Eric Stier________________________________
|
|
Eric Stier
|
|
Senior Vice President, General Counsel and Secretary
|
1 Year GenMark Diagnostics Chart |
1 Month GenMark Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions